Related Experiment Videos
[Comparative study of 2 antithrombotic regimens in 75 patients with coronary endoprostheses]
T Iturbe1, C Sánchez, J A Moreno
1Servicio de Hematología, Hospital Clínico Universitario de Zaragoza.
Insights
Antiplatelet therapy is a safer choice for coronary stent patients, showing fewer bleeding complications than systemic anticoagulation. This approach reduces risks without compromising stent patency.
Area of Science:
- Cardiology
- Pharmacology
- Vascular Medicine
Background:
- Coronary stents are crucial in treating coronary artery disease.
- Antithrombotic therapy is essential post-stenting to prevent complications.
- Comparing anticoagulation and antiplatelet strategies is vital for patient outcomes.
Purpose of the Study:
- To compare systemic anticoagulation versus antiplatelet therapy in patients with coronary stents.
- To evaluate differences in subacute stent occlusion, hospital stay, and hemorrhagic complications.
- To determine the optimal antithrombotic regimen for coronary stent recipients.
Main Methods:
- A study involving 75 patients with coronary stents divided into two groups.
- Group A (34 patients): received sodium heparin, acenocoumarin, acetylsalicylic acid, and dipyridamole.
- Group B (41 patients): received ticlopidine and aspirin (antiplatelet agents).
Main Results:
- One case (2.9%) of stent occlusion thrombosis occurred in Group A; none in Group B.
- Hemorrhagic complications were higher in Group A (32.3%) versus Group B (21.8%).
- Fewer blood transfusions were needed in Group B compared to Group A.
Conclusions:
- Antiplatelet regimens are a favorable option for patients with coronary stents.
- This approach offers a better safety profile regarding bleeding complications.
- Further research may refine the primary indications for each antithrombotic strategy.
Purpose:
To compare systemic anticoagulation with antiaggregation in patients with coronary stent, with regard to subacute occlusion, mean hospital staying and haemorrhagic complications.
Patients And Methods:
Seventy-five patients with coronary stent were treated with one of two different antithrombotic protocols. A group comprised of 34 patients (group A) received sodium heparin and acenocoumarin, plus acetylsalicylic acid (325 mg) and dipyridamole (225 mg). The remaining 41 patients (group B) were given antiplatelet agents, namely ticlopidine (125-250 mg) and aspirin (125 mg).
Results:
One case of group A (2.9%) showed thrombosis due to stent occlusion. No thrombotic complications were seen in the patients with antiplatelet drugs. Haemorrhagic complications were present in 11 group A patients (32.3%), and blood transfusion was necessary in 3 of them. Hemorrhage was present in 9 cases of group B (21.8%), and none of them needed blood transfusion. The mean number of days to achieve INR > 2 was 3.06 (1-11) in group and 2.02 (1-5) in group B.
Conclusions:
Antiplatelet regimes appear as a good choice in coronary stent, in spite of the fact that the primary indication seems that of group A.